Grifols, S.A. (GIFLF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Grifols, S.A. (GIFLF), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 52/100 puan alıyor.
Son analiz: 17 Mar 2026Grifols, S.A. (GIFLF) Sağlık ve Boru Hattı Genel Bakışı
Grifols, S.A., founded in 1940 and headquartered in Barcelona, is a global healthcare leader focused on plasma-derived therapies and diagnostic solutions. Operating across Bioscience, Hospital, Diagnostic, and Bio Supplies divisions, Grifols serves diverse healthcare needs, addressing chronic, rare, and life-threatening diseases with a comprehensive portfolio of products and services.
Yatırım Tezi
Grifols, S.A. presents a notable research candidate within the healthcare sector, driven by its leading position in plasma-derived therapies and diagnostic solutions. The company's consistent profitability, demonstrated by a 5.3% profit margin and 38.4% gross margin, underscores its operational efficiency. A key value driver is the increasing demand for plasma-derived products, fueled by an aging global population and advancements in medical treatments. Upcoming catalysts include the potential expansion of its product portfolio and geographic reach. However, investors should be aware of potential risks, including regulatory changes and competition from other players in the industry. Grifols' beta of 1.19 suggests a slightly higher volatility compared to the market, while its dividend yield of 1.60% provides a steady income stream for investors.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $8.78 billion reflects Grifols' significant presence in the healthcare industry.
- P/E ratio of 16.01 indicates a reasonable valuation compared to its earnings.
- Profit margin of 5.3% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 38.4% highlights the efficiency of Grifols' production and sales processes.
- Dividend yield of 1.60% provides a steady income stream for investors.
Rakipler & Benzerleri
Güçlü Yönler
- Leading position in plasma-derived therapies.
- Diversified product portfolio.
- Global presence and distribution network.
- Strong R&D capabilities.
Zayıflıklar
- Dependence on plasma supply.
- Exposure to regulatory changes.
- High R&D costs.
- Competition from other players in the industry.
Katalizörler
- Ongoing: Increasing demand for plasma-derived therapies due to the aging global population.
- Ongoing: Expansion of the company's product portfolio through R&D efforts.
- Upcoming: Potential strategic acquisitions to expand market share.
- Upcoming: Positive clinical trial results for new therapies in development.
- Ongoing: Geographic expansion into emerging markets with high growth potential.
Riskler
- Potential: Fluctuations in plasma prices could impact profitability.
- Ongoing: Intense competition from other players in the plasma-derived therapies market.
- Potential: Regulatory changes could impact the company's operations and financial performance.
- Potential: Product liability claims could result in significant financial losses.
- Ongoing: Economic downturns could reduce demand for the company's products and services.
Büyüme Fırsatları
- Expansion of Bioscience Division: Grifols can expand its Bioscience division by developing new plasma-derived therapies and increasing its market share in existing products. The global market for immunoglobulins, for example, is projected to reach $18.5 billion by 2028, presenting a significant growth opportunity for Grifols. This expansion can be achieved through increased R&D investment and strategic acquisitions.
- Geographic Expansion: Grifols has the opportunity to expand its geographic presence, particularly in emerging markets. These markets offer significant growth potential due to increasing healthcare spending and a growing demand for plasma-derived therapies. The company can leverage its existing infrastructure and partnerships to penetrate these markets effectively.
- Diagnostic Division Growth: The Diagnostic division can drive growth by developing and commercializing innovative diagnostic products that address unmet medical needs. The global market for diagnostic products is expected to grow at a CAGR of 5% over the next five years, driven by advancements in technology and increasing demand for personalized medicine. Grifols can capitalize on this trend by investing in R&D and strategic partnerships.
- Hospital Division Expansion: Grifols can expand its Hospital division by offering a wider range of non-biological pharmaceutical products, medical supplies, and medical devices. The global market for hospital supplies is projected to reach $45 billion by 2027, presenting a significant growth opportunity for Grifols. This expansion can be achieved through strategic acquisitions and partnerships.
- Bio Supplies Division Growth: The Bio Supplies division can drive growth by providing biological materials for life-science research, clinical trials, and manufacturing pharmaceutical and diagnostic products. The increasing demand for these materials, driven by advancements in biotechnology and personalized medicine, presents a significant growth opportunity for Grifols. The company can leverage its expertise and infrastructure to capitalize on this trend.
Fırsatlar
- Expansion into emerging markets.
- Development of new plasma-derived therapies.
- Growth in the diagnostic products market.
- Strategic acquisitions and partnerships.
Tehditler
- Fluctuations in plasma prices.
- Increased competition.
- Product liability claims.
- Economic downturns.
Rekabet Avantajları
- Specialized expertise in plasma-derived therapies.
- Extensive network of plasma donation centers.
- Strong relationships with healthcare providers and institutions.
- Proprietary manufacturing processes and technologies.
GIFLF Hakkında
Founded in 1940 in Barcelona, Spain, Grifols, S.A. has evolved into a global healthcare company specializing in plasma-derived therapies and diagnostic solutions. The company operates through four primary divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies. The Bioscience division is the core of Grifols' business, focusing on the research, development, production, and marketing of plasma-derived medicines. These therapies include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins, which are used to treat patients with chronic, rare, prevalent, and life-threatening diseases. The Hospital division provides non-biological pharmaceutical products, medical supplies, clinical nutrition products, intravenous therapy solutions, and medical devices. The Diagnostic division develops and commercializes diagnostic products used across the healthcare continuum, from prevention and screening to diagnosis, prognosis, and treatment monitoring. The Bio Supplies division offers biological materials for life-science research, clinical trials, and manufacturing pharmaceutical and diagnostic products. Grifols serves a wide range of customers, including public and private healthcare providers, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems. The company has a technology collaboration agreement with Mondragon, further enhancing its innovation capabilities. With a global presence and a commitment to innovation, Grifols is dedicated to improving patient outcomes and advancing healthcare worldwide.
Ne Yaparlar
- Procures plasma from donors.
- Manufactures therapeutic products from plasma.
- Develops and commercializes diagnostic products.
- Offers non-biological pharmaceutical products and medical supplies.
- Provides biological materials for life-science research.
- Markets plasma-derived medicines to treat chronic, rare, and life-threatening diseases.
İş Modeli
- Generates revenue from the sale of plasma-derived therapies.
- Earns revenue from the sale of diagnostic products and services.
- Profits from the sale of hospital supplies and medical devices.
- Derives income from providing biological materials for research and manufacturing.
Sektör Bağlamı
Grifols operates in the drug manufacturing industry, which is characterized by intense competition, stringent regulatory requirements, and high research and development costs. The global market for plasma-derived therapies is experiencing steady growth, driven by the increasing prevalence of chronic diseases and advancements in medical technology. Grifols competes with other major players in the industry, including BDUUF (B. Braun Melsungen AG), CSPCY (CSL Limited), ESAIY (Eisai Co., Ltd.), ESALF (EssilorLuxottica SA), and KYKOF (Kyowa Kirin Co., Ltd.). The company's focus on innovation and strategic partnerships positions it favorably within this competitive landscape.
Kilit Müşteriler
- Public and private healthcare providers
- Wholesalers and distributors
- Blood banks and hospitals
- National health systems
Finansallar
Grafik & Bilgi
Grifols, S.A. (GIFLF) hisse senedi fiyatı: Price data unavailable
Son Haberler
GIFLF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
GIFLF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
GIFLF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, GIFLF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Jose Ignacio Abia Buenache
CEO
Jose Ignacio Abia Buenache serves as the CEO of Grifols, S.A., leading a global workforce of 23,833 employees. His career history reflects a deep understanding of the healthcare industry, with extensive experience in strategic management and operational leadership. He is responsible for guiding Grifols' overall strategy, driving innovation, and ensuring the company's continued growth and success in the global market. His leadership is crucial in navigating the complexities of the plasma-derived therapies and diagnostic solutions sectors.
Sicil: Under Jose Ignacio Abia Buenache's leadership, Grifols has continued to expand its global presence and strengthen its position as a leader in plasma-derived therapies. Key achievements include strategic acquisitions, the development of innovative products, and the expansion of the company's R&D capabilities. His focus on operational efficiency and strategic partnerships has contributed to Grifols' consistent profitability and growth.
GIFLF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing requirements or regulatory oversight, which increases the risk for investors.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure increases the risk of investing in GIFLF.
- Lower trading volume and wider bid-ask spreads can lead to price volatility.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- The OTC market is generally more susceptible to market manipulation.
- Delays in trade execution due to lower liquidity.
- Verify the company's registration and regulatory filings.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Grifols, S.A. is a well-established company with a long operating history.
- The company has a global presence and serves a wide range of customers.
- Grifols is a leader in the plasma-derived therapies market.
- The company has a technology collaboration agreement with Mondragon.
- The company employs over 23,000 employees.
GIFLF Hakkında Sıkça Sorulan Sorular
GIFLF için değerlendirilmesi gereken temel faktörler nelerdir?
Grifols, S.A. (GIFLF) şu anda yapay zeka skoru 52/100, orta puanı gösteriyor. Temel güçlü yan: Leading position in plasma-derived therapies.. İzlenmesi gereken birincil risk: Potential: Fluctuations in plasma prices could impact profitability.. Bu bir finansal tavsiye değildir.
GIFLF MoonshotScore'u nedir?
GIFLF şu anda MoonshotScore'da 52/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
GIFLF verileri ne sıklıkla güncellenir?
GIFLF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler GIFLF hakkında ne diyor?
GIFLF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
GIFLF'a yatırım yapmanın riskleri nelerdir?
GIFLF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Fluctuations in plasma prices could impact profitability.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
GIFLF'ın P/E oranı nedir?
GIFLF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GIFLF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
GIFLF aşırı değerli mi, yoksa düşük değerli mi?
Grifols, S.A. (GIFLF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
GIFLF'ın temettü verimi nedir?
Grifols, S.A. (GIFLF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.